Pegylated interferons for chronic hepatitis B

Antiviral Research

Volumn 60, Issue 2, 2003, Pages 87-89

  Craxi, Antonio ^a   Cooksley, W Graham ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Royal Brisbane and Womens Hospital Research Foundation   (Australia)

Author keywords

Chronic hepatitis B; Interferon alpha; Peginterferon alpha 2a (40 kDa)

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A;

CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DNA VIRUS; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 0344012054     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.08.015     Document Type: Conference Paper

References (17)

1. Chien R.N., Liaw Y.F., Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 30:1999;770-774.
2. Cooksley, W.G.E., Piratvisuth, T., Mahachai, V., Chao, Y.C., Chutaputti, A., Chang, W.Y., Zahm, F.E., Pluck, N., 2002. Peginterferon alfa-2a (40 kDa) (PEGASYS) therapy for HBeAg-positive chronic hepatitis C (CHB): 48-week end-of-follow-up results and evaluation of the prognostic factors of response. In: Proceedings of the 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy.
3. Craxi A., Di Bona D., Cammà C., Interferon-α for HBeAg-positive chronic hepatitis B. J. Hepatol. 39:2003;S99-S105.
4. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., Balart L., Reindollar R., Reddy R.K., Wright T.L., Lin A., Hoffman J., De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343:2000;1673-1680.
5. Kao J.H., Wu N.H., Chen P.J., Lai M.Y., Chen D.S. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 33:2000;998-1002.
6. Kozlowski A., Charles S.A., Harris J.M. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs. 15:2001;419-429.
7. Lee C.M., Ong G.Y., Lu S.N., Wang J.H., Liao C.A., Tung H.D., Chen T.M., Changchien C.S. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J. Hepatol. 37:2002;669-674.
8. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology. 30:1999;567-572.
9. Lindsay K.L., Trepo C., Heintges T. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 34:2001;395-403.
10. Lok A.S., Hussain M., Cursano C., Margotti M., Gramenzi A., Grazi G.L., Jovine E., Benardi M., Andreone P. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 32:2000;1145-1153.
11. Niederau C., Heintges T., Lange S., Goldmann G., Niederau C.M., Mohr L., Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 334:1996;1422-1427.
12. Perrillo, R.P., Wright, T., Rakela, J., Levy, G., Schiff, E., Gish, R., Martin, P., Dienstag, J., Adams, P., Dickson, R., Anschuetz, G., Bell, S., Condreay, L., Brown, N., Lamivudine North American Transplant Group, 2001. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33, 424-432.
13. Song B.C., Suh D.J., Lee H.C., Chung Y.H., Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 32:2000;803-806.
14. Wai C.T., Chu C.J., Hussain M., Lok A.S. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 36:2002;1425-1430.
15. Wang Y.S., Youngster S., Bausch J. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry. 39:2000;10634-10640.
16. Wong D.K., Cheung A.M., O'Rourke K., Naylor C.D., Detsky A.S., Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Med. 119:1993;312-323.
17. Zeuzem S., Heathcote J.E., Martin N., Nieforth K., Modi M. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin. Investig. Drugs. 10:2001;2201-2213.